|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Dermatologic disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Poisoning, Inorganic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Nervous System, Organic Arsenic Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Encephalopathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Induced Polyneuropathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Heart Failure, Diastolic
|
0.300 |
Biomarker
|
disease |
CTD_human |
In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.
|
29556499 |
2018 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We showed by microarray and by RT-PCR that NDRG3 overexpression up-regulates the expression of many angiogenic chemokines including CXCL1 (chemokine ligand 1), CXCL3 (chemokine ligand 3) and CXCL5 (chemokine ligand 5), which may increase angiogenesis of tumors.
|
18975380 |
2009 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Molecular and functional characterization of tumor-induced factor (TIF): Hamster homolog of CXCL3 (GRO<sub>γ</sub>) displays tumor suppressive activity.
|
29276973 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
CCK-8, transwell assays and growth of tumor xenografts were conducted to characterize the effects of CXCL3 on PC-3 cells' proliferation and migration.
|
29524043 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 was reportedly associated with the invasion and metastasis of various malignancies, the role of CXCL3, however, in preeclampsia has not been fully discussed.
|
29884302 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 belongs to the CXC-type chemokine family and is known to play a multifaceted role in various human malignancies.
|
31667838 |
2020 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 and its receptor CXCR2 were considered to play particularly important roles in the progression of malignancies.
|
26837773 |
2016 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, GRO-3 was related to metastasis formation, and IL-8 was associated with survival, suggesting a potential predictive power of these markers.
|
20162422 |
2010 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CXCL3 was reportedly associated with the invasion and metastasis of various malignancies, the role of CXCL3, however, in preeclampsia has not been fully discussed.
|
29884302 |
2018 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The KRAS<sup>∗</sup>-IRF2-CXCL3-CXCR2 axis provides a framework for patient selection and combination therapies to enhance the effectiveness of ICB therapy in CRC.
|
30905761 |
2019 |